Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341209 · ClinicalTrials.gov registry record · Phase 2
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
A Phase 2 study, sponsored by Rochester General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02341209 is a Phase 2 study that was terminated before completion, run by Rochester General Hospital. The registered enrollment target is 1 participants.
The verdict
NCT02341209, a Phase 2 study, was terminated before completion, sponsored by Rochester General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.
Interventions
- DRUG Doxycycline monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2021-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341209
The ClinicalTrials.gov registry entry for NCT02341209 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rochester General Hospital, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxycycline monohydrate is the first listed.
NCT02341209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02341209 about?
NCT02341209 is a clinical study titled "Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma". This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.
What is the current status of trial NCT02341209?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2018-02-06. Estimated completion is 2021-02-06.
What interventions are being tested in trial NCT02341209?
The interventions under investigation include: Doxycycline monohydrate (DRUG).
Who is sponsoring clinical trial NCT02341209?
This trial is sponsored by Rochester General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.